EXHIBIT 12.1

	Ratio of Earnings to Fixed Charges
	(dollars in thousands, except ratio data)
	Year ended December 31,
	2010			2009		2008			2007			2006
Earnings (Loss):
Earnings (loss) before provision for income taxes	$	(233,231	)	$	4,385	$	(268,891	)	$	(284,371	)	$	(264,087	)
Fixed Charges		78,108			77,780		82,930			80,927			59,505
Total Earnings (Loss)	$	(155,123	)	$	82,165	$	(185,961	)	$	(203,444	)	$	(204,582	)
Fixed Charges:
Interest expense on indebtedness (including amortization of debt expense and discount)	$	59,500		$	58,424	$	62,912		$	60,716		$	39,606
Interest expense on portion of rent expense representative of interest		18,608			19,356		20,018			20,211			19,899
Total Fixed Charges	$	78,108		$	77,780	$	82,930		$	80,927		$	59,505
Ratio of Earnings to Fixed Charges		—			1.06		—			—			—
Coverage deficiency (1)(2)(3)	$	(233,231	)	$	—	$	(268,891	)	$	(284,371	)	$	(264,087	)

(1)	The Company’s Ratio of Earnings to Fixed Charges for 2009 includes a gain on extinguishment debt of $38,873, a gain on sale of an equity investment of $5,259 and reflects revenues received in connection with the delivery of raxibacumab to the Strategic National Stockpile. These amounts should not be considered indicative of the Company’s future performance.
(2)	The Company’s Coverage deficiency for 2008 includes a gain on the sale of an equity investment of $32,518 partially offset by a charge for impaired investment of $6,284.
(3)	The Company’s Coverage deficiency for 2006 includes charges for facility-related exit charges of $29,510 partially offset by a gain on the sale of an equity investment of $14,759.